WINTERVILLE, N.C. - NantHealth (OTC:NHIQ), Inc. (NASDAQ-GS: NH), a healthcare enterprise solution provider, recently announced the appointment of Scott Maratea as Chief Revenue Officer. Maratea brings over three decades of experience to the role, having previously held the position of Chief Revenue Officer at Curve Health and Life Image, Inc.
In his new capacity, Maratea will be tasked with spearheading the sales and revenue generation strategies for NantHealth. His extensive background in healthcare technology and strategic leadership is expected to contribute to the company's growth and market expansion.
The CEO of NantHealth, Haris Naseem, MD, expressed confidence in Maratea's ability to drive revenue growth and deliver value to customers, highlighting his proven track record and industry expertise.
Maratea's role will involve close collaboration with the executive team to develop and implement strategic initiatives aimed at increasing revenue and enhancing the company's presence in the healthcare sector.
NantHealth is part of the NantWorks ecosystem and offers enterprise solutions that enable the transformation of complex data into actionable insights, serving the healthcare, life sciences, logistics, telecommunications, and other industries.
This leadership update is based on a press release statement and is part of NantHealth's ongoing efforts to strengthen its executive team and position itself for future success in the healthcare market.
InvestingPro Insights
NantHealth, Inc. (NASDAQ-GS: NH) has shown notable financial metrics that could be of interest to investors following the recent executive appointment. The company's market capitalization stands at a robust $3.09 billion, indicating a significant presence in the healthcare solutions market. As of the last twelve months leading up to Q1 2025, NantHealth reported a healthy revenue growth of 8.38%, with an even slightly higher quarterly revenue growth of 8.72% in Q1 2025. This consistent growth trajectory suggests that the firm is expanding its financial base, which may be further bolstered by Scott Maratea's expertise in revenue generation.
Investors looking for profitability metrics would note the company's P/E ratio, which is 32.48, adjusted slightly downward to 31.92 for the last twelve months as of Q1 2025. This valuation measure, coupled with a PEG ratio of 1.71, might indicate expectations for future earnings growth, aligning with the strategic goals set by Maratea and the executive team.
With an eye on profitability, NantHealth's gross profit margin stands at a solid 40.76%, reflecting the company's ability to maintain a significant difference between sales and the cost of goods sold. This is a critical aspect for investors to consider, especially as the company positions itself for market expansion under the new Chief Revenue Officer's guidance.
For those interested in dividend income, NantHealth has a dividend yield of 0.32%, and a notable dividend growth of 60.0% in the last twelve months as of Q1 2025, which could appeal to income-focused investors.
An InvestingPro Tip highlights that NantHealth's price is currently at 87.75% of its 52-week high, which may suggest room for growth or a potential buying opportunity for investors. Additionally, the company's fair value, as estimated by analysts, is at $16.58, while InvestingPro's own fair value calculation stands at $13.18, offering different perspectives on the company's valuation.
For investors eager for more in-depth analysis, InvestingPro offers several additional tips on NantHealth, providing a more comprehensive investment picture.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.